A Phase 2 interventional study of 1.25 g PA21 (250 mg iron) and 5.0 g PA21 (1,000 mg iron) in Chronic Kidney Disease, sponsored by Vifor Pharma. Completed at 60 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-01.
Sponsored by Vifor Pharma (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing sevelamer in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Sevelamer · Renal Insufficiency, Chronic.
Among the 20 studies testing sevelamer in Renal Insufficiency, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 9th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →1 of the 20 studies testing sevelamer in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 50+
By country, each count listing its studies:
Sevelamer: first FDA approval 1998 (RENAGEL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 67 across the 20 interventional studies. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Vifor Pharma, one of the names counted as CSL Limited. Under that name alone:
Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.
15 studies in Renal Insufficiency, Chronic by CSL Limited: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Renal Insufficiency, Chronic by CSL Limited, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 2, and was the 1st registered.
CSL Limited’s Renal Insufficiency, Chronic studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing sevelamer in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among CSL Limited’s 15 in Renal Insufficiency, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 1.25 g PA21 (250 mg iron)
Drug: 5.0 g PA21 (1,000 mg iron)
Drug: 7.5 g PA21 (1,500 mg iron)
Drug: 10.0 g PA21 (2,000 mg iron)
Drug: 12.5 g PA21 (2,500 mg iron)
Drug: Sevelamer hydrochloride
Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Change From Baseline in Serum-phosphate Levels at the End of Treatment.
Time frame: 6 weeks after baseline
Change From Baseline in Serum-phosphate Levels at Week 2
Time frame: 2 weeks after baseline
Change From Baseline in Serum-phosphate Levels at Week 4
Time frame: 4 weeks after baseline
Change From Baseline in Serum-phosphate Levels at Week 5
Time frame: 5 weeks after baseline
| Milestone | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5 g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| Started | 26 | 26 | 25 | 27 | 24 | 26 |
| Completed | 18 | 17 | 20 | 15 | 15 | 18 |
| Not completed | 8 | 9 | 5 | 12 | 9 | 8 |
| mmol/L | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| Change From Baseline in Serum-phosphate Levels at the End of Treatment. | -0.042 ± 0.650 | -0.348 ± 0.684 | -0.404 ± 0.391 | -0.644 ± 0.551 | -0.547 ± 0.584 | -0.341 ± 0.436 |
| mmol/L | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5 g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| Change From Baseline in Serum-phosphate Levels at Week 2 | -0.03 ± 0.55 | -0.36 ± 0.35 | -0.41 ± 0.40 | -0.47 ± 0.62 | -0.46 ± 0.45 | -0.41 ± 0.44 |
| mmol/L | 1.25 g PA21 (250 mg Iron) | 5.0g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| Change From Baseline in Serum-phosphate Levels at Week 4 | -0.03 ± 0.39 | -0.39 ± 0.45 | -0.32 ± 0.54 | -0.58 ± 0.53 | -0.53 ± 0.48 | -0.53 ± 0.35 |
| mmol/L | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5 g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| Change From Baseline in Serum-phosphate Levels at Week 5 | -0.05 ± 0.62 | -0.51 ± 0.62 | -0.40 ± 0.33 | -0.57 ± 0.55 | -0.58 ± 0.58 | -0.52 ± 0.37 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.25 g PA21 (250 mg Iron) | — | 2/26 (7.7%) | 13/26 (50%) |
| 5.0 g PA21 (1,000 mg Iron) | — | 2/26 (7.7%) | 16/26 (61.5%) |
| 7.5 g PA21 (1,500 mg Iron) | — | 1/25 (4%) | 13/25 (52%) |
| 10.0 g PA21 (2,000 mg Iron) | — | 1/27 (3.7%) | 18/27 (66.7%) |
| 12.5 g PA21 (2,500 mg Iron) | — | 2/24 (8.3%) | 17/24 (70.8%) |
| Sevelamer Hydrochloride - Active Control | — | 2/26 (7.7%) | 13/26 (50%) |
| Event | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5 g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| Staphylococcal sepsisInfections and infestations | 0/26 | 1/26 | 0/25 | 0/27 | 1/24 | 0/26 |
| Fluid overloadMetabolism and nutrition disorders | 0/26 | 0/26 | 0/25 | 0/27 | 1/24 | 0/26 |
| Ischaemic strokeNervous system disorders | 0/26 | 0/26 | 1/25 | 0/27 | 0/24 | 0/26 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/26 | 0/26 | 0/25 | 0/27 | 0/24 | 0/26 |
| Diverticular perforationGastrointestinal disorders | 1/26 | 0/26 | 0/25 | 0/27 | 0/24 | 0/26 |
| Myocardial infarctionCardiac disorders | 0/26 | 1/26 | 0/25 | 0/27 | 0/24 | 0/26 |
| CholelithiasisHepatobiliary disorders | 0/26 | 0/26 | 0/25 | 0/27 | 0/24 | 1/26 |
| Diabetic retinopathyEye disorders | 0/26 | 0/26 | 0/25 | 0/27 | 0/24 | 1/26 |
| Rib fractureInjury, poisoning and procedural complications | 0/26 | 0/26 | 0/25 | 1/27 | 0/24 | 0/26 |
| Event | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5 g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control |
|---|---|---|---|---|---|---|
| HypophosphataemiaMetabolism and nutrition disorders | 2/26 | 4/26 | 2/25 | 8/27 | 7/24 | 2/26 |
| HyperphosphataemiaMetabolism and nutrition disorders | 4/26 | 3/26 | 1/25 | 1/27 | 0/24 | 2/26 |
| Faeces DiscoloureGastrointestinal disorders | 2/26 | 3/26 | 3/25 | 4/27 | 3/24 | 0/26 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/26 | 1/26 | 2/25 | 1/27 | 3/24 | 0/26 |
| AnaemiaBlood and lymphatic system disorders | 0/26 | 0/26 | 3/25 | 0/27 | 0/24 | 0/26 |
| HypotensionVascular disorders | 0/26 | 1/26 | 0/25 | 0/27 | 0/24 | 3/26 |
| HypertensionVascular disorders | 1/26 | 0/26 | 2/25 | 0/27 | 2/24 | 1/26 |
| NasopharyngitisInfections and infestations | 0/26 | 0/26 | 0/25 | 0/27 | 2/24 | 0/26 |
| DiarrhoeaGastrointestinal disorders | 1/26 | 2/26 | 2/25 | 1/27 | 1/24 | 2/26 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/26 | 2/26 | 1/25 | 1/27 | 1/24 | 2/26 |
For baseline characteristics data, from All Randomised patients was used.
| Age, Categorical(Participants) | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 18 | 14 | 17 | 14 | 16 | 93 |
| >=65 years | 12 | 8 | 11 | 10 | 10 | 10 | 61 |
| Age, Continuous(years) | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control | Total |
|---|---|---|---|---|---|---|---|
| Mean | 60.1 ± 12.29 | 59.7 ± 13.80 | 61.9 ± 13.71 | 60.6 ± 12.74 | 59.3 ± 12.32 | 61.1 ± 11.00 | 60.5 ± 12.50 |
| Sex: Female, Male(Participants) | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control | Total |
|---|---|---|---|---|---|---|---|
| Female | 9 | 7 | 9 | 10 | 11 | 11 | 57 |
| Male | 17 | 19 | 16 | 17 | 13 | 15 | 97 |
| Region of Enrollment(participants) | 1.25 g PA21 (250 mg Iron) | 5.0 g PA21 (1,000 mg Iron) | 7.5 g PA21 (1,500 mg Iron) | 10.0 g PA21 (2,000 mg Iron) | 12.5g PA21 (2,500 mg Iron) | Sevelamer Hydrochloride - Active Control | Total |
|---|---|---|---|---|---|---|---|
| United States | 4 | 4 | 3 | 4 | 2 | 4 | 21 |
| Czech Republic | 0 | 3 | 0 | 0 | 3 | 2 | 8 |
| Poland | 4 | 2 | 3 | 2 | 0 | 4 | 15 |
| Romania | 2 | 4 | 2 | 3 | 1 | 0 | 12 |
| Croatia | 5 | 3 | 9 | 8 | 8 | 7 | 40 |
| Russian Federation | 7 | 5 | 3 | 5 | 2 | 6 | 28 |
| Bulgaria | 3 | 3 | 5 | 4 | 7 | 1 | 23 |
| Germany | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Switzerland | 0 | 2 | 0 | 1 | 1 | 1 | 5 |
The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 4 years 6 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iron · Sevelamer
Renal Insufficiency, Chronic →